Effect of MY008211A on Heart Rhythm in Healthy Adults
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a single oral dose of a new medicine (MY008211A) to see how it affects the heart's electrical activity (QT interval) in healthy volunteers. It is a Phase 1 trial to check for safety before moving to larger studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy adult between 18 and 45 years old.
- Your body mass index (BMI) is between 19.0 and 26.0.
- You weigh at least 110 pounds (50 kg) for men, or 100 pounds (45 kg) for women.
- You have no history of heart rhythm problems (like long QT syndrome) or family history of sudden cardiac death.
- You are not currently taking any medications or supplements (including over-the-counter drugs).
- You are willing to avoid alcohol, smoking, and certain foods (like grapefruit) during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This study tests a new oral medication called NTQ5082 for people with PNH who have not been treated with a complement inhibitor before. It aims to see if the drug can reduce the breakdown of red blood cells and improve anemia.
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
This trial tests the long-term safety and effectiveness of NTQ5082 for people who have already taken part in a previous NTQ5082 study and benefited from it, or who were in the control group and received eculizumab. It aims to see if continued treatment is safe and helpful over a longer period.
This study is for people with paroxysmal nocturnal hemoglobinuria (PNH) who have already taken the experimental drug HSK39297. It checks the long-term safety of continuing the treatment and makes sure it is still helpful.
This study checks the long-term safety of the drug MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH). It is only for those who already took the drug in an earlier study and had benefit, and who have had specific vaccines.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.